

## **LABELLING**

## **PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

HDPE bottle

### **1. Name of the medicinal product**

[HA392 trade name]<sup>\*</sup> Lamivudine/Zidovudine 150 mg/300 mg Tablets  
Lamivudine/Zidovudine

### **2. Statement of active substance**

Each film-coated tablet contains 150 mg lamivudine and 300 mg zidovudine.

### **3. List of excipients**

### **4. Pharmaceutical form and contents**

60 film coated tablets

### **5. Method and route of administration**

Oral use.

Read the patient information leaflet before use.

### **6. Special warning that the medicinal product must be stored out of the reach and sight of children**

Keep this medicine out of the sight and reach of children.

### **7. Other special warning(s), if necessary**

Read the package leaflet before use

### **8. Expiry date**

EXP {MM/YYYY}

### **9. Special storage conditions**

Do not store above 30°C. Store in the original package

### **10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate**

### **11. Name and address of the supplier**

Mylan Laboratories Limited

---

<sup>\*</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

<sup>#</sup> Formerly known as "Matrix Lab. Ltd".

Plot No. 564/A/22, Road No.92, Jubilee Hills  
Hyderabad – 500096  
Telangana,  
India  
Email: ProductSafety@viatris.com

**12. WHO Reference Number (Prequalification Programme)**

HA392

**13. Manufacturer's batch number**

<Batch> <Lot> {number}

**14. (Advice on) General classification for supply**

{Medicinal product subject to medical prescription.}

**15. Instructions on use**